<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767752</url>
  </required_header>
  <id_info>
    <org_study_id>GI 1604</org_study_id>
    <nct_id>NCT02767752</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer</brief_title>
  <acronym>CHIPAC</acronym>
  <official_title>A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) With or Without T-ChOS as Adjuvant Therapy in Patients With Surgically Resected Pancreatic Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GENIS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, double-blind, placebo-controlled phase II trial that&#xD;
      will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as&#xD;
      adjuvant treatment for 6 months in patients with surgically resected pancreatic&#xD;
      adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual and change of SOC (FOLFIRINOX in adjuvant setting)&#xD;
  </why_stopped>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>up to approximately 9 months</time_frame>
    <description>Time from the date of randomization to the date of disease recurrence or death, whichever is earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to approximately 18 months</time_frame>
    <description>Time from the date of randomization to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to approximately 18 months</time_frame>
    <description>Assesment by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to approximately 18 months</time_frame>
    <description>Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determination of plasma YKL-40</measure>
    <time_frame>up to approximately 9 months</time_frame>
    <description>Measurement using an enzyme linked-immunosorbent assay</description>
  </other_outcome>
  <other_outcome>
    <measure>Determination of plasma IL-6</measure>
    <time_frame>up to approximately 9 months</time_frame>
    <description>Measurement using an enzyme linked-immunosorbent assay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>T-ChOS + Gemcitabine + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.&#xD;
Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Gemcitabine + Capecitabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.&#xD;
Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>T-ChOS</intervention_name>
    <arm_group_label>T-ChOS + Gemcitabine + Capecitabine</arm_group_label>
    <other_name>Benecta™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Placebo + Gemcitabine + Capecitabine</arm_group_label>
    <arm_group_label>T-ChOS + Gemcitabine + Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Gemcitabine + Capecitabine</arm_group_label>
    <other_name>Sugar pill manufactured to mimic 300 mg capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Placebo + Gemcitabine + Capecitabine</arm_group_label>
    <arm_group_label>T-ChOS + Gemcitabine + Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic&#xD;
             complete resection (R0 and R1). Subjects with neuroendocrine (and mixed type) tumors&#xD;
             are excluded&#xD;
&#xD;
          3. Subject should be able to start treatment no later than 12 weeks post-surgery&#xD;
&#xD;
          4. Male or non-pregnant, non-lactating females who are ≥18 years of age at the time of&#xD;
             signing the informed consent form (ICF)&#xD;
&#xD;
          5. ECOG/WHO Performance Status (PS) 0-1&#xD;
&#xD;
          6. Females of child-bearing potential (defined as a sexually mature woman who (1) has not&#xD;
             undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy&#xD;
             [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal&#xD;
             for at least 24 consecutive months [i.e., has had menses at any time during the&#xD;
             preceding 24 consecutive months]) must:&#xD;
&#xD;
               -  Agree to the use of two physician-approved contraceptive methods (oral,&#xD;
                  injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine&#xD;
                  device; barrier contraceptive with spermicide; or vasectomized partner) while on&#xD;
                  study IP; and for 3months following the last dose of IP&#xD;
&#xD;
               -  Has negative serum pregnancy test (β-hCG) result at screening&#xD;
&#xD;
          7. Male subjects:&#xD;
&#xD;
             • Must practice true abstinence or agree to use a condom during sexual contact with a&#xD;
             pregnant female or a female of childbearing potential while participating in the&#xD;
             study, during dose interruptions and for 6 months following IP discontinuation, even&#xD;
             if he has undergone a successful vasectomy&#xD;
&#xD;
          8. Understand and voluntarily sign an ICF prior to any study related assessments or&#xD;
             procedures being conducted&#xD;
&#xD;
          9. Be able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
         10. Acceptable hematology parameters defined as:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 10⁹/L&#xD;
&#xD;
               -  Haemoglobin ≥ 5.6 mmol/L&#xD;
&#xD;
         11. Acceptable liver function defined as:&#xD;
&#xD;
               -  Serum bilirubin &lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  ASAT/ALAT &lt; 2.5 x ULN&#xD;
&#xD;
         12. Acceptable renal function with a creatinine clearance ≥ 50 mL/min/ (e.g., using the&#xD;
             Cockroft-Gault formula)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic&#xD;
             adenocarcinoma&#xD;
&#xD;
          2. Presence of or history of metastatic or locally recurrent pancreatic adenocarcinoma&#xD;
&#xD;
          3. Other malignancies, except adequately treated basal carcinoma or squamous cell&#xD;
             carcinoma of the skin or in situ cervix carcinoma or incidental prostate cancer (T1a,&#xD;
             Gleason score ≤ 6, PSA &lt; 0.5 ng/ml), or any other tumor with a DSF survival of ≥ 5&#xD;
             years&#xD;
&#xD;
          4. History of serious or concurrent illness or uncontrolled medical disorder; any medical&#xD;
             condition that might be aggravated by chemotherapy treatment or which could not be&#xD;
             controlled; including, but not restricted to:&#xD;
&#xD;
               -  Active infection requiring antibiotics within 2 weeks before the study inclusion&#xD;
&#xD;
               -  Concurrent congestive heart failure NYHA class III - IV&#xD;
&#xD;
               -  Unstable angina pectoris, or myocardial infarction within 6 months and/or prior&#xD;
                  poorly controlled hypertension&#xD;
&#xD;
               -  History of interstitial lung disease, slowly progressive dyspnea and unproductive&#xD;
                  cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary&#xD;
                  hypersensitivity pneumonitis or multiple allergies&#xD;
&#xD;
               -  Concomitant use of immunosuppressive or myelosuppressive medications that would&#xD;
                  in the opinion of the investigator, increase the risk of serious neutropenic&#xD;
                  complications&#xD;
&#xD;
          5. Known or suspected allergy to the investigational agents or any agents given in&#xD;
             association with this trial&#xD;
&#xD;
          6. Any psychological, familial, sociological, or geographical condition which does not&#xD;
             permit protocol compliance and medical follow-up&#xD;
&#xD;
          7. Enrollment in any other clinical protocol or investigational study with an&#xD;
             interventional agent or assessments that may interfere with study procedures&#xD;
&#xD;
          8. Any condition including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study&#xD;
&#xD;
          9. Any condition that confounds the ability to interpret data from the study&#xD;
&#xD;
         10. Unwillingness or inability to comply with study procedures&#xD;
&#xD;
         11. Current use of anticoagulation therapy such as heparins both unfractionated and low&#xD;
             molecular weighted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inna Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev &amp; Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>July 7, 2018</last_update_submitted>
  <last_update_submitted_qc>July 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inna Chen, MD</investigator_full_name>
    <investigator_title>Staff specialist</investigator_title>
  </responsible_party>
  <keyword>Resectable pancreatic cancer</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

